Previous 10 | Next 10 |
ADC Therapeutics (NYSE:ADCT) said on May 9 that Co-Founder Chris Martin stepped down as CEO and the company appointed Ameet Mallik to replace him in the role. Mallik served for 16 years at Novartis (NVS), most recently as executive vice president and Head of U.S. Oncology. ADC ...
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q1 2022 Earnings Call May 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q1 2022 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2022 Earnings Conference Call May 09, 2022 08:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Chris Martin - Former Chief Executive Officer Jennifer Herron - Chief Commercial Officer Joe Camardo - Chief Medical Officer Jenn Creel - Chie...
The following slide deck was published by ADC Therapeutics SA in conjunction with their 2022 Q1 earnings call. For further details see: ADC Therapeutics SA 2022 Q1 - Results - Earnings Call Presentation
ADC Therapeutics press release (NYSE:ADCT): Q1 Non-GAAP EPS of -$0.36. Revenue of $46.5M beats by $12.57M. For further details see: ADC Therapeutics Non-GAAP EPS of -$0.36, revenue of $46.5M beats by $12.57M
Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $16.5 million in the first quarter of 2022 Company to host conference call today at 8:30 a.m. EDT ADC Therapeutics SA ...
Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that its executives ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that a permanent J-c...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...